Packaging Design QuickFire Challenge: Unit Dose Technologies

Awardees

Overview

As the science and innovation behind products evolve, so must the packaging of those products. Advancing additional options for unit dose packaging may represent the next generation of medication storage.

In the US, the wider adoption of non-reclosable unit dose packaging has been limited due to concern for user-friendly access and design[1], non-recyclable packaging waste, manufacturability and speed at which packaging lines can operate[2].

In addition to helping to prevent accidental unsupervised ingestions (AUIs) of medications by children, some unit dose packaging configurations have also shown to increase medication adherence[3], improve monitoring[4], and reduce risk of contamination[5]. While strides have been made in packaging safety[6], AUIs, when young children self-ingest medicines which are not appropriately kept high and out of sight and reach, can lead to overdose and preventable injury[7].

To inspire innovators to bring potentially groundbreaking unit dose packaging options to the market – with a focus on child-resistant, user-friendly, non-reclosable designs - Johnson & Johnson Innovation together with the packaging innovation team within Johnson & Johnson Consumer Inc. is launching thePackaging Design QuickFire Challenge: Unit Dose Technologies.Potential innovations can include both solids (tablets, capsules and powders) and liquids (solutions and suspensions) in unit-dose formats (e.g. blisters, sachets and stick packs). Primary and secondary packaging or combination of the two are in scope of the challenge.

The innovator(s) with the best idea, potential technology, or potential solution will receive grant funding from a total pool of up to $100,000, access to the global Johnson & Johnson Innovation – JLABS network and mentorship from experts across the Johnson & Johnson Family of Companies.

* Subject to the execution of the necessary documentation and (award) agreements

Application Process

Submissions are expected to focus on the “main criteria” shown below. The “criteria to also consider” will help you differentiate your submission from the rest and the applicant is expected to elaborate on how these criteria can be or not be addressed.

Main criteria:

• 儿童耐药和用户友好的包装,covers the range of F1 through the F9 **
• Aim for unit-dose non-reclosable formats.
• Provides great user experience. Some examples of this are: ease of use/opening, frustration-free opening, portability, attractiveness.
• Novelty of the idea.

Criteria to also consider:

• Increased sustainability.
• Easily integrates into existing packaging lines with minimal modification
• Support to patience adherence.
• Cost-effective, scalable & manufacturable
• Tamper evidence.
• Barrier needs of pharmaceuticals.
• Safety of opening and ingestion. (e.g. user cutting due to sharp edges of packaging)

** Ideas are not expected to have a test certificate but should consider as a reference to the16 CFR § 1700.20. In general, a child resistant and user friendly test consists of two parts. For the first part, a child must not access to “F” amount of unit doses in a period of 10 minutes. F1 means test failure when a child accesses to 1 unit dose. F9 means failure when a child accesses to 9 unit doses. The second part of the test is the user friendly test. A user should be able to open the packaging in a period of 1 minute.

Why this challenge matters to us

At Johnson & Johnson Innovation, we believe a good idea can come from anywhere, and it’s our goal to find innovative health solutions that aim to improve health around the world. We know that despite parents’ and caregivers’ best efforts at preventing accidental unsupervised ingestions they occur. Working together, we can spark the next great idea that can potentially change the trajectory of health for adults and children around the world.

About Johnson & Johnson Innovation

ld乐动强生公司创新有限责任公司在工作pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us atwww.jnjinnovation.com.

About Johnson & Johnson Consumer Inc.

At Johnson & Johnson Consumer Health, we are driven to improve the personal health of people everywhere. Our differentiated portfolio of iconic brands, including Tylenol®, Zarbee's®, Neutrogena®, Aveeno®, Listerine®, OGX®, and Johnson's®, delivers life-enhancing, first-to-market innovation. By combining the power of science with meaningful human insights and digital-first thinking, we help more than 1.2 billion people live healthier lives every day, from their very first day.